SCHEMBL770301

SCHEMBL770301

O=C(CCN1C(=O)c2ccccc2C1=O)N1CCC2CCCC=C2C1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.64
ALDH1A1 P00352 7/20 0.57
HSD17B10 Q99714 4/20 0.57
HPGD P15428 3/20 0.57
KMT2A Q03164 2/20 0.57
GAA P10253 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 3/20 0.53
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.53
TSHR P16473 2/20 0.50
ALOX15 P16050 1/20 0.50
TP53 P04637 1/20 0.49
ACHE P22303 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769681 0.94 SMN1; SMN2 (0.65) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL770679 0.93 ALDH1A1 (0.64) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771252 0.89 HSD17B10 (0.53) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771366 0.88 MAPK1 (0.52) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771256 0.88 MAPK1 (0.50) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL772471 0.88 MAPK1 (0.49) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771730 0.83 SMN1; SMN2 (0.52) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL770981 0.82 ALDH1A1 (0.52) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771359 0.82 SMN1; SMN2 (0.52) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771240 0.82 SMN1; SMN2 (0.53) MAPK1ALDH1A1HSD17B10HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPK1 401/4885ALDH1A1 144/4885HSD17B10 19/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPK1 410/4885ALDH1A1 142/4885HSD17B10 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.